Bluejay announces U.S. manufacturing partnership with Argonaut

On June 2, 2026, Bluejay Diagnostics, Inc. (NASDAQ: BJDX) and Argonaut Manufacturing Services announced a strategic partnership to support the advancement of the company's Symphony platform. Bluejay says the partnership is designed to support its efforts to establish scalable U.S.-based manufacturing capabilities aligned with its clinical development programs and future commercialization.

Why the partnership matters to Bluejay

The release says the partnership is intended to strengthen Bluejay's future commercial infrastructure by supporting broader product distribution across the United States. It also says the arrangement is meant to enhance supply-chain resilience and reduce potential risks associated with international sourcing and import tariffs. Bluejay describes its current reliance on overseas manufacturing as a risk that the partnership is intended to mitigate by establishing domestic capabilities.

According to the company, U.S.-based manufacturing and distribution can give it greater operational control, business continuity and supply-chain security. Bluejay says these changes should improve its operational flexibility and its ability to commercialize its near-patient diagnostic products for critical care settings.

About Argonaut

Argonaut Manufacturing Services is a contract manufacturing organization focused on supporting life sciences and diagnostics companies with high-quality manufacturing solutions. The release says it was founded by former executives of companies including Thermo Fisher Scientific, Affymetrix and Allergan.

Rick Hancock, Chief Executive Officer of Argonaut Manufacturing Services, said: "We value this collaboration with Bluejay Diagnostics and look forward to supporting their efforts as they continue to develop solutions aimed at improving clinical decision-making in critical care settings."

Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics, said the partnership reflects the company's commitment to building a scalable and quality-focused operational foundation as it progresses toward key commercial milestones.

What Bluejay does

Bluejay describes itself as a medical diagnostics company focused on improving patient outcomes with its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Its first product candidate, an IL-6 Test for sepsis, is designed to provide accurate results in approximately 20 minutes. The company says the Symphony System does not yet have regulatory clearance, and that it will need FDA authorization before Symphony can be marketed as a diagnostic product in the United States.

The SYMON-II study is the pivotal study that Bluejay plans to use to support a 510(k) application to the FDA. The company also runs SYMON-I, a pilot study of IL-6 levels, and SYMON-III, a pilot study in emergency department patients at risk of sepsis.

Financial position

The release does not include financial terms, a contract value or a volume commitment. Bluejay's XBRL financial data, drawn from its annual report filed March 6, 2026, shows a net income (loss) of negative $6.8 million for the fiscal year ended December 31, 2025, and research and development expense of $3.0 million for the same year. For 2024 the figures were negative $7.7 million and $3.5 million.

What is still missing

The announcement is a statement of intent. It says the partnership is designed, intended and aimed at outcomes, and it sets no start date, capacity, cost or quantity. The company concedes it currently relies on overseas manufacturing, so the domestic capability does not yet exist, and the tariff and import-risk benefits are the company's own claims. Argonaut's chief executive offered only that he looked forward to supporting Bluejay's efforts. Bluejay lost $6.8 million in 2025 and used $6.1 million of cash in operations, and the release says nothing about how the manufacturing build-out will be paid for. The release does not give dates for the partnership's next steps. It says the Symphony IL-6 Test has not been cleared or approved by the FDA and is not currently available for commercial clinical use in the United States. The company plans to use its SYMON-II pivotal study to support a 510(k) application, and it describes the Symphony platform as an investigational device limited by United States law to investigational use.

Report an error

Companies in this story

BJDXBluejay Diagnostics, Inc.NASDAQ · United StatesOpen the starter desk